Compare AMPY & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPY | LUCD |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.9M | 198.4M |
| IPO Year | 2011 | 2021 |
| Metric | AMPY | LUCD |
|---|---|---|
| Price | $3.99 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 942.0K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.26 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,637,000.00 | $4,346,000.00 |
| Revenue This Year | N/A | $115.58 |
| Revenue Next Year | $23.83 | $130.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $3.12 | $0.90 |
| 52 Week High | $6.79 | $1.63 |
| Indicator | AMPY | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 53.74 |
| Support Level | $3.86 | $1.02 |
| Resistance Level | $4.92 | $1.12 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 27.64 | 75.47 |
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The companies oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.